Filing 00 · Case Summary
Turing Pharmaceuticals — The Daraprim Controversy
Turing Pharmaceuticals raised the price of Daraprim from $13.50 to $750 per pill in 2015. Complete factual record of the controversy, criminal case, and antitrust settlement.
A.
Index of Filings
14 entries
File 02 · The Acquisition
About Turing Pharmaceuticals LLC
Turing Pharmaceuticals LLC was founded in February 2015, acquired Daraprim for $55M, and rebranded as Vyera Pharmaceuticals in 2017.
File 01 · The Drug
What Is Daraprim (Pyrimethamine)? — Medical Profile, History, Uses
Daraprim (pyrimethamine) is the standard treatment for toxoplasmosis, approved by the FDA in 1953. Drug profile, mechanism, patient populations, pricing history, and generic availability.
File 03 · The Increase
The Daraprim Price Hike: From $13.50 to $750
In September 2015, Turing Pharmaceuticals raised the price of Daraprim from $13.50 to $750 per pill — a 5,455% increase. Timeline, justifications, hospital impact, and aftermath.
File 04 · The Founder
Martin Shkreli — Biography, Trial, Conviction, and Outcome
Martin Shkreli founded Turing Pharmaceuticals and raised the price of Daraprim 5,455%. Biography from Brooklyn to prison, securities fraud conviction, and lifetime pharma ban.
File 05 · Hearings
The 2016 Congressional Hearings on Daraprim
Two 2016 congressional hearings examined the Daraprim price hike. Shkreli invoked the Fifth Amendment. Insider testimony revealed no R&D justification. Full hearing record.
File 07 · Antitrust
FTC v. Vyera Pharmaceuticals — The Antitrust Case and Settlement
The FTC filed an antitrust case against Vyera Pharmaceuticals in 2020 for blocking generic Daraprim. Settlement required $1/tablet pricing, $40M payment, and Shkreli's lifetime pharma ban.
File 08 · Generic
Generic Pyrimethamine — When It Arrived and Who Makes It
Generic pyrimethamine became available in February 2020 after Vyera blocked competition for five years. Current manufacturers, pricing, and how the FTC forced market entry.
File 06 · Patients
Daraprim and Patients — The Human Cost of the Price Hike
How the Daraprim price hike affected real patients and hospitals. The Weston family, hospital cost data, prescribing collapse, and what the patient assistance programme actually delivered.
File 10 · Disease
Toxoplasmosis — The Disease That Made Daraprim Essential
Toxoplasmosis is a parasitic infection that can be fatal for HIV/AIDS patients and immunocompromised individuals. Why pyrimethamine (Daraprim) remains the standard treatment.
File 09 · Rebrand
From Turing Pharmaceuticals to Vyera — The Rebrand
Turing Pharmaceuticals rebranded as Vyera Pharmaceuticals in September 2017. The name changed but pricing and anticompetitive practices continued under new leadership.
File 11 · Leadership
Turing Pharmaceuticals Leadership Team
Profiles of Turing Pharmaceuticals executives: Martin Shkreli, Ron Tilles, Kevin Mulleady, Nancy Retzlaff, and Howard Dorfman. Roles, actions, and outcomes.
File 12 · Coverage
Daraprim News Coverage — What Was Reported and When
Chronological record of major Daraprim news coverage from September 2015 through 2024, including the NYT report, congressional hearings, conviction, and FTC settlement.
File 13 · Statements
Turing Pharmaceuticals Press Releases — Official Statements with Context
Official press releases and public statements from Turing Pharmaceuticals during 2015-2016, presented with factual context on each claim.